---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-305412"
form_type: "8-K"
ticker: "SYBX"
cik: "0001527599"
company_name: "SYNLOGIC, INC."
filed_at: "2022-12-15T23:59:59+00:00"
generated_at: "2026-06-21T04:07:36.244633+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Synlogic reports SYNB8802 Phase 1b proof of concept: -38% urinary oxalate reduction in enteric hyperoxaluria

## Summary
- SYNB8802 reduced urinary oxalate by 38% vs placebo at 3x10^11 TID dose in Roux-en-Y gastric bypass patients.
- No serious adverse events; GI AEs mild and similar in frequency between active and placebo groups.
- Third positive clinical readout for Synlogic in 2022, following SYNB1934 for PKU and SYNB1353 for homocystinuria.
- Company to host webcast today at 8:30 AM ET with Dr. Kyle Wood of UAB.

## SEC filing metadata
- accession: 0001193125-22-305412
- form_type: 8-K
- ticker: SYBX
- cik: 0001527599
- company_name: SYNLOGIC, INC.
- filed_at: 2022-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527599/000119312522305412/0001193125-22-305412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527599/000119312522305412/d426522d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-305412
- JSON: https://secwatch.observer/filing/0001193125-22-305412.json
- Plain text: https://secwatch.observer/filing/0001193125-22-305412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.